Metamizole () antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-201-Ag01	BSA-Metamizole	756
GMP-SMT-201-Ag02	OVA-Metamizole	756
GMP-SMT-201-Ab01	Anti-Metamizole mouse monoclonal antibody (mAb)	1953
GMP-SMT-201-Ab02	Anti-Metamizole human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-201-Ag01
Product Name	BSA-Metamizole
Target/Biomarker	Metamizole(NULL)
Expression platform	Synthetic
Bioactivity validation	Metamizole (NULL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Metamizole (NULL) / OVA-Metamizole (NULL) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-201-Ag02
Product Name	OVA-Metamizole
Target/Biomarker	Metamizole(NULL)
Expression platform	Synthetic
Bioactivity validation	Metamizole (NULL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Metamizole (NULL) / OVA-Metamizole (NULL) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-201-Ab01
Product Name	Anti-Metamizole mouse monoclonal antibody (mAb)
Target/Biomarker	Metamizole(NULL)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Human Metamizole (NULL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Metamizole (NULL) antibodies in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human Metamizole (NULL) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-201-Ab02
Product Name	Anti-Metamizole human monoclonal antibody (mAb)
Target/Biomarker	Metamizole(NULL)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Human Metamizole (NULL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Metamizole (NULL) antibodies in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human Metamizole (NULL) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Metamizole, a chemically recognized entity as Dipyrone, assumes a paramount role in the intricate domain of in vitro diagnosis (IVD). Its involvement within IVD is substantiated by its crucial positioning as an antigenic target of profound significance. In essence, Metamizole is meticulously integrated into diagnostic assays in conjunction with our repository of anti-small molecules antibodies and small molecules competitive antigens. This strategic amalgamation collectively empowers the precise, specific, and quantitative detection of antibodies or immune responses explicitly directed towards Metamizole. The necessity to measure Metamizole encompasses an array of clinical, pharmacological, and scientific dimensions, each underpinned by its own rationale: a. Toxicity Assessment: Metamizole has not been immune to reports of potential adverse effects and adverse drug reactions. This inherent pharmacological complexity underscores the paramount importance of vigilant monitoring. The measurement of Metamizole-specific antibodies or immune responses within clinical specimens serves as a linchpin in the identification of individuals at an elevated risk of adverse reactions. This, in turn, facilitates the formulation of precise and informed clinical decisions, minimizing the potential for detrimental outcomes. b. Therapeutic Monitoring: The widespread use of Metamizole as an analgesic and antipyretic medication underscores the necessity for accurate and diligent therapeutic monitoring. Precise dosing and the assessment of therapeutic efficacy are integral to optimizing patient care and minimizing the risks associated with either suboptimal or excessive drug administration. The measurement of Metamizole levels within patient samples stands as a sentinel for therapeutic adequacy, offering healthcare providers invaluable insights into the therapeutic landscape. c. Pharmacovigilance: Comprehensive assessment of Metamizole exposure, coupled with an intricate understanding of ensuing immune responses, confers substantial benefits to the overarching sphere of pharmacovigilance. This multifaceted approach empowers regulatory authorities and healthcare providers with the tools required to expeditiously identify and effectively manage potential safety concerns linked to the medication. The insights garnered from this vigilant scrutiny contribute to the enhancement of patient safety and the informed utilization of Metamizole within the clinical spectrum. d. Scientific Advancement: Beyond its clinical implications, Metamizole serves as an invaluable resource within the realm of scientific research. This compound's intrinsic ability to elicit immune responses and its potential involvement in adverse reactions provides fertile ground for scientific exploration. The utilization of Metamizole as a research tool facilitates the in-depth study of immune reactions and adverse events associated with the drug. These investigations, conducted at a molecular and cellular level, not only enrich our scientific understanding but also underpin the development of enhanced diagnostic methodologies and safer pharmaceutical formulations. In summation, the measurement of Metamizole within the purview of IVD transcends its role as a mere diagnostic parameter. It represents a multifaceted endeavor encompassing safety assessment, therapeutic optimization, pharmacovigilance, and scientific progress. Metamizole's integral contribution to patient care, reinforcement of pharmacological vigilance, and its role in the refinement of diagnostic methodologies collectively yield tangible dividends in terms of improved healthcare outcomes and patient well-being. The nexus between Metamizole and IVD stands as a testament to the intricate synergy between clinical practice, pharmacology, and scientific advancement.

About GDU